This study from PDXNet shows high concordance of key driver mutations in patient derived xenografts (PDXs) and corresponding human tumors which provide therapeutic targets for future PDX drug response trials

https://urldefense.com/v3/__https://www.nature.com/articles/s41467-021-25177-3__;!!PfbeBCCAmug!3p0VwMt0XOi7gDmxWKeUttfLzuy4_3YpH4uXiKz5uOXi4y2fpuUi1TX9MC8a0liU$